Gamma-interferon-induced monocyte major histocompatibility complex class II antigen expression individuals with acquired immune deficiency syndrome.
Twelve patients with the acquired immune deficiency syndrome (AIDS) and Kaposi's sarcoma were treated with recombinant human gamma-interferon (rIFN-gamma). A rapid, substantial increase in the fraction of HLA-DQ-positive monocytes was noted after treatment with rIFN-gamma. The rIFN-gamma-induced increase in monocyte HLA-DQ was seen throughout the course of treatment, with the percentage of HLA-DQ-positive monocytes dropping slightly following each week's treatment with rIFN-gamma and then rapidly increasing following the next course of treatment. Although the percentage of HLA-DR-positive monocytes was unchanged (HLA-DR was expressed on greater than 80% of monocytes prior to treatment), the density of HLA-DR on monocytes also increased following rIFN-gamma treatment. Following rIFN-gamma treatment, no changes were seen in CD3, CD4, CD8 T cell numbers, in T cell subset ratio (CD4/CD8), in Leu 7 or CD16 (Leu 11) cell number, in spontaneous Ig secretion, in PHA-induced in vitro proliferation, or in NK activity. These results indicate that exposure to rIFN-gamma in vivo led to the increased expression of class II antigens on monocytes in patients with AIDS.
Martínez-Maza
O
O
Department of Microbiology and Immunology, UCLA School of Medicine 90024.
Mitsuyasu
R T
RT
Miles
S A
SA
Giorgi
J V
JV
Heitjan
D F
DF
Sherwin
S A
SA
Fahey
J L
JL
D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology* / Q000628:therapy; D004305:Dose-Response Relationship, Drug; D006681:HLA-D Antigens / Q000276:immunology*; D006801:Humans; D007113:Immunity, Innate; D007136:Immunoglobulins / Q000378:metabolism; D007371:Interferon-gamma / Q000494:pharmacology* / Q000627:therapeutic use; D007694:Killer Cells, Natural / Q000276:immunology; D007958:Leukocyte Count / Q000187:drug effects; D008213:Lymphocyte Activation / Q000187:drug effects; D008214:Lymphocytes / Q000276:immunology; D009000:Monocytes / Q000276:immunology*; D011994:Recombinant Proteins; D012514:Sarcoma, Kaposi / Q000276:immunology* / Q000628:therapy
D006681:HLA-D Antigens; D007136:Immunoglobulins; D011994:Recombinant Proteins; D007371:Interferon-gamma